

Presence of Eosinophils in Nasal Secretion during Acute Respiratory Tract Infection in Young Children Predicts Subsequent Wheezing within Two Months

Miwa Shinohara^{1,2,3}, Hiroshi Wakiguchi¹, Hirohisa Saito³ and Kenji Matsumoto³

ABSTRACT

Background: In young children with wheezing or bronchiolitis, especially with respiratory syncytial virus, blood eosinophilia and a high eosinophil cationic protein level in nasal secretions predicts subsequent wheezing in later childhood. However, whether eosinophil activation results from virus-induced inflammation or local eosinophilia per se precedes the onset of wheezing remains unknown. In the present study, we examined the association between the presence of nasal eosinophils during respiratory tract infection (RTI) and subsequent wheezing in young children.

Methods: A total of 35 young children less than 3 years of age who visited our outpatient clinic with rhinorrhea between April and July 2004 were enrolled in this prospective cohort study. Subjects who were given diagnoses of allergic rhinitis were excluded. In all the subjects, the presence of eosinophils in nasal secretions was determined. The subjects were followed, and the cumulative incidences of wheezing during the subsequent 2- and 12-month periods were examined.

Results: According to a logistic regression analysis adjusted for age, sex, family history, allergies, and wheezing at entry, young children with nasal eosinophil infiltration during acute RTI had a significantly higher risk of wheezing during the subsequent 2 months, compared with those without nasal eosinophil infiltration (adjusted odds ratio, 27.618, $p = 0.016$).

Conclusions: Our findings not only suggest that nasal eosinophil testing may serve as a convenient clinical marker for identifying young children at risk for subsequent wheezing, but also shed new light on the role of eosinophils in the onset of wheezing in young children.

KEY WORDS

eosinophils, nasal secretion, respiratory tract infection, wheezing, young children

INTRODUCTION

Wheezing is a very common symptom of lower respiratory tract infection (RTI) in infants; 34% of infants experience at least one wheezing episode by the age of 3 years, while 49% experience at least one episode by the age of 6.¹ The small absolute size of the airways, airway edema, mucus hypersecretions, im-

paired humoral protections and immature immune responses render infants and young children particularly susceptible to airway obstruction and can cause wheezing.^{2,3} The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life. In a substantial minority of infants, however, wheezing episodes

¹Department of Pediatrics, Kochi Medical School, ²Department of Pediatrics, Noichi Central Hospital, Kochi and ³Department of Allergy and Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.
Correspondence: Kenji Matsumoto, MD, PhD, Department of Allergy and Immunology, National Research Institute for Child

Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Email: kmatsumoto@nch.go.jp

Received 15 February 2008. Accepted for publication 9 May 2008.

©2008 Japanese Society of Allergy

are probably related to a predisposition to asthma.¹ Stein *et al.* have reported three different wheezing phenotypes in childhood: “transient early wheezing”, “non-atopic wheezing” and “IgE-associated wheeze/asthma”.⁴ They also showed that only one third of wheezing infants exhibit persistent wheezing at any age with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.

Bronchiolitis is one of the most severe types of lower RTI in infancy and is the most common disease requiring the hospitalization of infants among developed countries.⁵ Approximately 70% of viral bronchiolitis is caused by respiratory syncytial virus (RSV) infection.⁶ However, RSV is a common pathogen for RTIs among all age groups, especially during the winter season, and the symptoms of most patients with RSV infection are restricted to within the upper airways.^{7,8} Thus, additional factors, such as Th2-deviated immune responses⁹ or allergic predispositions,¹⁰ are thought to play some roles in the onset of RSV-induced lower RTI, including bronchiolitis. RSV bronchiolitis in early childhood is an important risk factor for the subsequent development of asthma.^{11,12}

In infants with wheezing or bronchiolitis, it is extremely important to investigate useful clinical markers capable of distinguishing early asthma patients from transient early wheezers to initiate possible early intervention or primary prevention strategies. For this purpose, a clinical index for defining the risk of asthma in young children with recurrent wheezing has been investigated.¹³ Along with a familial history of asthma and a past history of atopic dermatitis, peripheral blood eosinophilia has been reported to be a valuable marker for predicting subsequent wheezing.¹³ In addition, the serum eosinophil cationic protein (ECP) levels at the time of the first wheezing episode¹⁴ and the nasal ECP levels^{15,16} were also reported to be strong predictors of subsequent wheezing and asthma.

In infants with bronchiolitis, a number of investigators have reported similar findings—namely, that blood eosinophilia¹⁷⁻¹⁹ and elevated serum ECP levels predict the onset of subsequent wheezing,²⁰⁻²³ even though neutrophil activation is reportedly correlated with disease severity.^{24,25} However, some controversial observations have also been reported.^{22,26} Such controversy may be due to differences between local immune responses and peripheral blood testing.²⁷⁻³⁰ For example, in patients with abundant eosinophil accumulation in the lung during the acute phase of bronchiolitis, the eosinophil ratio in the peripheral blood may be relatively low. Therefore, markers of local eosinophil activation should be expected; ECP^{22,31} or RANTES³² concentrations in nasal lavage fluid or nasal discharge during bronchiolitis have also been reported to be highly predictive of subsequent wheezing.

These findings strongly suggest that local eosino-

philic inflammation during wheezing or bronchiolitis is positively associated with subsequent wheezing in young children with wheezing episodes or bronchiolitis. However, whether eosinophil activation results from virus-induced inflammation or local eosinophilia per se precedes the onset of wheezing remains unknown. This point is of particular interest for determining the role of eosinophils in the formation of wheezing in young children. In the present study, we prospectively examined the association between the presence of nasal eosinophils during RTI and subsequent wheezing in young children.

METHODS

SUBJECTS

A total of 35 young children (19 boys and 16 girls, age 6–33 months) who visited our outpatient clinic in Kochi, Japan, between April and July, 2004, and whose chief complaint was rhinorrhea were enrolled in this prospective cohort study. None of the subjects had experienced more than one wheezing episode prior to enrollment. Subjects who had been given diagnoses of allergic rhinitis by a physician were excluded from the study.

Informed consent was obtained from the parents of all the participating subjects, and the study was approved by the Ethics Review Board of Kochi Medical School.

METHODS

At the time of entry, the parents of the subjects answered a questionnaire regarding the age, sex, and the history of physician-diagnosed allergic diseases, including atopic dermatitis, food allergy, asthma, allergic conjunctivitis and urticaria, of both the subjects and their parents.

Nasal secretions were sampled during the first visit by swabbing the bilateral middle one-third inferior turbinates with cotton swabs. The samples were spread onto a slide glass, air-dried, fixed, and stained with Wright-Giemsa solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan). The samples were then evaluated for the presence or absence of eosinophils by examining 5 high power fields (HPFs) with a light microscope (Olympus, Tokyo, Japan).

The subjects were further examined by the same pediatrician 2 and 12 months after the first visit. The cumulative incidences of wheezing during the follow-up periods were then determined.

STATISTICS

A logistic regression model adjusted for age, sex, family history, allergic diseases in the subjects, wheezing at study entry, and eosinophils in the nasal secretion was analyzed using STATA software (Stata-Corp LP, College Station, TX, USA) and considered to be significant when $p < 0.05$. The post-estimated goodness of fit (Hosmer-Lemeshow) was confirmed

Table 1 Descriptive characteristics of the subjects at study entry and the presence or absence of eosinophils in nasal secretions

Characteristics †	Total		Eosinophils in nasal secretions				p value
	(N = 35)		Yes (N = 16)		No (N = 19)		
Age (months) ‡	16.5	(6–33)	18.2	(6–32)	15.0	(6–33)	0.407
Sex (M/F) §	19/16	(54)	10/6	(63)	9/10	(47)	0.371
Wheezing at study entry (Y/N) §	14/21	(40)	8/8	(50)	6/13	(32)	0.268
Family history §	16/19	(46)	8/8	(50)	8/11	(42)	0.640
Allergic diseases in the subject ¶							
Atopic dermatitis	5/30	(14)	1/15	(7)	4/15	(21)	0.347
Food allergy	7/28	(20)	2/14	(13)	5/14	(26)	0.415
Asthma	4/31	(11)	2/14	(13)	2/17	(11)	1.000

† Mean value or the number in the population, and the percentage or range.

‡ Two-sample Wilcoxon rank-sum (Mann-Whitney) test.

§ χ^2 test.

¶ Fisher's exact test.

Table 2 Laboratory findings for peripheral blood samples at study entry and the presence or absence of eosinophils in nasal secretions

Laboratory findings †	Total		Eosinophils in nasal secretions		p value ‡		
	(N = 21)		Yes (N = 11)	No (N = 10)			
Total IgE (IU/mL)	472.1	(5–2700)	546.8	(5–2700)	667.6	(5–2100)	0.898
Percent of eosinophil (%)	4.9	(0–32)	5.3	(0–32)	4.4	(0.7–10)	0.934
Number of eosinophils (/mm ³)	486.5	(0–3648)	537.3	(0–3648)	430.6	(48.3–1150)	0.933

† Mean value or the number in the population and the percentage or range are shown.

‡ Two-sample Wilcoxon rank-sum (Mann-Whitney) test.

for all logistic regression analyses. The χ^2 test, Fisher's exact test and Wilcoxon rank-sum (Mann-Whitney) test were also performed using STATA software.

RESULTS

All 35 subjects completed the 12-month study. The descriptive characteristics of the subjects at entry are shown in Table 1. Age, sex, presence of wheezing at entry, family history of allergic diseases and allergic diseases in the subject were not associated with the presence or absence of eosinophils in the nasal secretions at entry (Table 1). The total IgE level, peripheral blood eosinophil ratio, and the number of eosinophils also were not associated with the presence or absence of eosinophils in the nasal secretions at entry (Table 2). In addition, both the maternal and paternal histories of any allergic diseases, particularly allergic rhinitis or asthma, were not associated with the presence or absence of eosinophils in the nasal secretion at entry (data not shown).

The age of infection has been reported to regulate cytokine production and disease patterns later in

life.³³ Sex and a family history of allergic diseases are well-known to be associated with the risk of allergic diseases during childhood.⁴ In addition, children with wheezing episodes tend to wheeze more than those without episodes.¹ To evaluate the effects of these confounding factors, a logistic regression model adjusted for age, sex, family history, allergic diseases in the subject and presence or absence of wheezing at entry was analyzed (Table 3). According to the logistic regression analysis, young children with nasal eosinophil infiltration during acute RTI had a significantly higher risk of wheezing during the subsequent 2-month period than those without nasal eosinophil infiltration (adjusted odds ratio (OR) 27.618; $p = 0.016$). The presence of wheezing at study entry was also a strong risk factor for subsequent wheezing (adjusted OR, 20.324; $p = 0.024$), as expected.¹

In contrast, nasal eosinophil infiltration during acute RTI was not associated with the risk of wheezing during the subsequent 12-month period (adjusted OR, 4.099; $p = 0.161$; Table 4).

Table 3 Effect of age, sex, allergic diseases in the subject, family history, eosinophils in nasal secretions and wheezing at study entry on the risk of wheezing during the subsequent 2 months

Variable	Total	Wheezing positive	(%)	Crude OR (95% CI)	† Adjusted OR (95% CI)	<i>p</i> value
Age	35	15	(43)	1.012 (0.939–1.090)	1.048 (0.929–1.181)	0.445
Sex						
Male	19	7	(37)	1.000	1.000	
Female	16	8	(50)	1.714 (0.443–6.629)	1.240 (0.186–8.254)	0.824
Allergic diseases in the subjects						
No	21	10	(48)	1.000	1.000	
Yes	14	7	(50)	1.000 (0.284–4.256)	3.919 (0.293–52.414)	0.302
Family history of allergic diseases						
No	19	10	(53)	1.000	1.000	
Yes	16	5	(31)	0.409 (0.102–1.640)	0.267 (0.032–2.218)	0.222
Wheezing at study entry						
No	21	7	(33)	1.000	1.000	
Yes	14	8	(57)	2.667 (0.661–10.751)	20.342 (1.480–279.619)	0.024 *
Eosinophils in nasal secretions						
No	19	7	(37)	1.000	1.000	
Yes	16	8	(50)	1.714 (0.443–6.629)	27.618 (1.859–410.201)	0.016 *

† Adjusted for age, sex, family history, allergic diseases in the subject, eosinophils in nasal secretions and wheezing at study entry.

**p* < 0.05.

Table 4 Effect of age, sex, allergic diseases in the subject, family history, eosinophils in nasal secretions and wheezing at study entry on the risk of wheezing during the subsequent 12 months

Variable	Total	Wheezing positive	(%)	Crude OR (95% CI)	† Adjusted OR (95% CI)	<i>p</i> value
Age	35	15	(43)	1.012 (0.939–1.090)	1.001	0.977
Sex						
Male	19	7	(37)	1.000	1.000	
Female	16	8	(50)	1.714 (0.443–6.629)	3.287 (0.582–18.571)	0.178
Allergic diseases in the subject						
No	21	7	(33)	1.000	1.000	
Yes	14	8	(57)	2.667 (0.661–10.751)	5.128 (0.751–35.020)	0.095
Family history of allergic diseases						
No	19	10	(53)	1.000	1.000	
Yes	16	5	(31)	0.409 (0.102–1.640)	0.296 (0.060–1.458)	0.161
Wheezing at study entry						
No	21	7	(33)	1.000	1.000	
Yes	14	8	(57)	2.667 (0.661–10.751)	2.488 (0.438–14.127)	0.304
Eosinophils in nasal secretions						
No	19	7	(37)	1.000	1.000	
Yes	16	8	(50)	1.714 (0.443–6.629)	4.099 (0.577–29.500)	0.161

† Adjusted for age, sex, family history, allergic diseases in the subject, eosinophils in nasal secretions, and wheezing at study entry.

DISCUSSION

In young children with wheezing and in young children with bronchiolitis, especially as a result of RSV infection, blood eosinophilia and nasal ECP predict subsequent wheezing. To test whether eosinophil activation is a result of virus-induced inflammation or local eosinophilia per se precedes the formation of

wheezing, we prospectively examined the association between the presence of nasal eosinophils during RTI and subsequent wheezing in young children. As a result, we found that children with eosinophil infiltration in their nasal secretions during RTI were more likely to experience episodes of wheezing during the subsequent 2 months. The lack of association between the number of peripheral blood eosinophils

and the presence of nasal eosinophils (Table 2) suggests the presence of some specific mechanisms attracting eosinophils to the nasal mucosa during RTI in young children.

Nasal eosinophils probably do not play a direct role in the lower airway. However, recent studies have demonstrated that allergic inflammation in the upper airway is closely related to allergic inflammation in the lower airway; this phenomenon is now referred to as "One Airway, One Disease".³⁴ In other words, patients with nasal eosinophil infiltration tend to have eosinophil infiltration in their lungs as well.

Among the virus-induced chemokines that are present in the lung,³⁵ RANTES is known to recruit,³⁶ prime and activate eosinophils *in vitro*.³⁷ Eosinophil activation, especially leukotriene production, may participate in the formation of allergic inflammation and may cause wheezing. As a matter of fact, the levels of leukotrienes, but not of prostaglandin D₂, are elevated in the bronchoalveolar lavage fluid of young children with persistent wheezing, suggesting that eosinophil activation, but not mast cell activation, plays critical roles in the formation of inflammatory reactions in the lung, particularly in young children.³⁸ In addition, anti-inflammatory therapy with oral corticosteroid³⁹ or with leukotriene antagonists⁴⁰ reduced the incidence of subsequent wheezing in children with bronchiolitis. However, a recent early interventional study with intermittent inhaled corticosteroids from infancy failed to alter the onset of asthma.⁴¹ Further investigations are surely needed to determine whether treatment with corticosteroids or leukotriene antagonists can modify the natural course of asthma in young children.

Our findings strongly suggest that the detection of nasal eosinophils during RTI may be a clinically useful marker of the risk of subsequent wheezing. Young children with nasal eosinophil infiltration during acute RTI should receive early interventions; practically speaking, this means that the avoidance of irritants, including passive smoke,⁷ and the avoidance of the aeroallergen exposure to diminish allergic sensitization⁴² should be strongly recommended.

In a previous study, the effect of eosinophil activation during bronchiolitis on the increased risk of asthma persisted until adulthood.²⁷ In our study, however, nasal eosinophil infiltration during RTI showed a positive association only with the near-term risk of wheezing (2 months), but not with the long-term risk of wheezing (12 months). This may reflect the fact that eosinophils accumulating in the airway survive only a short period of time and require an additional supply from the peripheral blood to maintain the allergic inflammatory reactions that cause recurrent wheezing.

This study has some limitations. First, virus detection was not performed in any of the subjects, although the study was performed during the non-RSV

season.⁸ Host immune responses against individual viruses are not the same^{16,43,44}; eosinophil-recruiting chemokines are strongly produced and released from bronchial epithelial cells after *in vitro* stimulation with RSV.^{45,46} Eosinophils have been reported to be activated by RSV-induced chemokines,³⁷ by RSV directly,⁴⁷ and by RSV-infected epithelial cells through CD18-mediated interactions.⁴⁸ Thus, whether the association between nasal eosinophils and subsequent wheezing is affected by different types of viruses should be further examined. Second, the number of eosinophils in the nasal secretions was only qualified, but not quantified. Determining whether an association exists between the number of infiltrating eosinophils and subsequent wheezing would be a point of interest. Finally, 14 subjects exhibited wheezing at study entry, even though the number of wheezing episodes had been no more than one. In this context, the subjects were not considered to have "upper respiratory tract infections".¹⁵ However, the subject population was typical of that visiting private outpatient clinics; as mentioned earlier, wheezing is a very common symptom in infancy and occurs in approximately one third of infants under 3 years of age.¹ In addition, our logistic regression model for analyzing the effect of the presence of nasal eosinophils on subsequent wheezing included an adjustment for the effect of wheezing at study entry.

Our findings strongly suggest that eosinophil activation precedes an allergic symptom, wheezing, in subjects with RTI. Our findings were compatible with our previous observation that eosinophilia in the cord blood preceded the onset of infantile eczema.⁴⁹ However, whether eosinophils play important roles in the onset of allergic diseases or are just a marker of allergic symptoms remains uncertain, even though eosinophils certainly play critical roles in airway remodeling.⁵⁰ In conclusion, the present findings not only suggest that nasal eosinophil testing may serve as a convenient clinical marker for identifying young children at risk for subsequent wheezing, but also shed new light on the role of eosinophils in the onset of wheezing in young children.

ACKNOWLEDGEMENTS

This work was supported in part by a grant from the "Foundation for Life" Charitable Trust of The Kochi Shinbun and Kochi Broadcasting (to M. S.) and a grant from the National Institute of Biomedical Innovation (ID05-41) (to K. M.).

REFERENCES

1. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. *N Engl J Med* 1995;**332**:133-8.
2. Stocks J. Respiratory physiology during early life. *Monaldi Arch Chest Dis* 1999;**54**:358-64.

3. Oh JW. Respiratory viral infections and early asthma in childhood. *Allergol Int* 2006;**55**:369-72.
4. Stein RT, Holberg CJ, Morgan WJ *et al*. Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood. *Thorax* 1997;**52**:946-52.
5. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. *JAMA* 1999;**282**:1440-6.
6. Anderson LJ, Heilman CA. Protective and disease-enhancing immune responses to respiratory syncytial virus. *J Infect Dis* 1995;**171**:1-7.
7. Duff AL, Pomeranz ES, Gelber LE *et al*. Risk factors for acute wheezing in infants and children: viruses, passive smoke, and IgE antibodies to inhalant allergens. *Pediatrics* 1993;**92**:535-40.
8. Gern JE, Busse WW. The role of viral infections in the natural history of asthma. *J Allergy Clin Immunol* 2000;**106**:201-12.
9. Renzi PM, Turgeon JP, Yang JP *et al*. Cellular immunity is activated and a TH-2 response is associated with early wheezing in infants after bronchiolitis. *J Pediatr* 1997;**130**:584-93.
10. Nagayama Y, Sakurai N, Nakahara T *et al*. Allergic predisposition among infants with bronchiolitis. *J Asthma* 1987;**24**:9-17.
11. Stein RT, Sherrill D, Morgan WJ *et al*. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *Lancet* 1999;**354**:541-5.
12. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. *Am J Respir Crit Care Med* 2000;**161**:1501-7.
13. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med* 2000;**162**:1403-6.
14. Koller DY, Wojnarowski C, Herkner KR *et al*. High levels of eosinophil cationic protein in wheezing infants predict the development of asthma. *J Allergy Clin Immunol* 1997;**99**:752-6.
15. Ingram JM, Rakes GP, Hoover GE, Platts-Mills TA, Heymann PW. Eosinophil cationic protein in serum and nasal washes from wheezing infants and children. *J Pediatr* 1995;**127**:558-64.
16. Rakes GP, Arruda E, Ingram JM *et al*. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. *Am J Respir Crit Care Med* 1999;**159**:785-90.
17. Ehlenfield DR, Cameron K, Welliver RC. Eosinophilia at the time of respiratory syncytial virus bronchiolitis predicts childhood reactive airway disease. *Pediatrics* 2000;**105**:79-83.
18. Martinez FD, Stern DA, Wright AL, Taussig LM, Halonen M. Differential immune responses to acute lower respiratory illness in early life and subsequent development of persistent wheezing and asthma. *J Allergy Clin Immunol* 1998;**102**:915-20.
19. Calvo Rey C, Garcia Garcia M, Albanil Ballesteros M. [Bronchiolitis and persistent wheezing. Is eosinophilia a risk factor?]. *An Esp Pediatr* 2001;**55**:511-6 (in Spanish).
20. Reijonen TM, Korppi M, Kuikka L *et al*. Serum eosinophil cationic protein as a predictor of wheezing after bronchiolitis. *Pediatr Pulmonol* 1997;**23**:397-403.
21. Pifferi M, Ragazzo V, Caramella D, Baldini G. Eosinophil cationic protein in infants with respiratory syncytial virus bronchiolitis: predictive value for subsequent development of persistent wheezing. *Pediatr Pulmonol* 2001;**31**:419-24.
22. Sigurs N, Bjarnason R, Sigurbergsson F. Eosinophil cationic protein in nasal secretion and in serum and myeloperoxidase in serum in respiratory syncytial virus bronchiolitis: relation to asthma and atopy. *Acta Paediatr* 1994;**83**:1151-5.
23. Miyoshi M. [Measurement of serum eosinophil cationic protein levels in wheezing infants]. *Arerugi [Jpn J Allergol]* 2002;**51**:1147-52 (in Japanese).
24. Marguet C, Bocquel N, Benichou J *et al*. Neutrophil but not eosinophil inflammation is related to the severity of a first acute epidemic bronchiolitis in young infants. *Pediatr Allergy Immunol* 2007;**19**:157-65.
25. Yoshihara S, Yamada Y, Abe T, Linden A, Arisaka O. Association of epithelial damage and signs of neutrophil mobilization in the airways during acute exacerbations of paediatric asthma. *Clin Exp Immunol* 2006;**144**:212-6.
26. Oymar K, Bjerknes R. Is serum eosinophil cationic protein in bronchiolitis a predictor of asthma? *Pediatr Allergy Immunol* 1998;**9**:204-7.
27. Piippo-Savolainen E, Remes S, Korppi M. Does blood eosinophilia in wheezing infants predict later asthma? A prospective 18-20-year follow-up. *Allergy Asthma Proc* 2007;**28**:163-9.
28. Shields MD, Brown V, Stevenson EC *et al*. Serum eosinophilic cationic protein and blood eosinophil counts for the prediction of the presence of airways inflammation in children with wheezing. *Clin Exp Allergy* 1999;**29**:1382-9.
29. Priftis KN, Papadopoulou A, Liatsis E, Katsikas D, Nicolaidou P, Kanariou M. Serum eosinophil cationic protein and CD23 in acute RSV bronchiolitis. *Med Sci Monit* 2005;**11**:CR493-7.
30. Pizzichini E, Pizzichini MM, Efthimiadis A, Dolovich J, Hargreave FE. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. *J Allergy Clin Immunol* 1997;**99**:539-44.
31. Reijonen TM, Korppi M, Kleemola M *et al*. Nasopharyngeal eosinophil cationic protein in bronchiolitis: relation to viral findings and subsequent wheezing. *Pediatr Pulmonol* 1997;**24**:35-41.
32. Chung HL, Kim SG. RANTES may be predictive of later recurrent wheezing after respiratory syncytial virus bronchiolitis in infants. *Ann Allergy Asthma Immunol* 2002;**88**:463-7.
33. Culley FJ, Pollott J, Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. *J Exp Med* 2002;**196**:1381-6.
34. Grossman J. One airway, one disease. *Chest* 1997;**111**:11S-6S.
35. Gern JE, French DA, Grindle KA, Brockman-Schneider RA, Konno S, Busse WW. Double-stranded RNA induces the synthesis of specific chemokines by bronchial epithelial cells. *Am J Respir Cell Mol Biol* 2003;**28**:731-7.
36. Bochner BS. Road signs guiding leukocytes along the inflammation superhighway. *J Allergy Clin Immunol* 2000;**106**:817-28.
37. Fujisawa T, Kato Y, Nagase H *et al*. Chemokines induce eosinophil degranulation through CCR-3. *J Allergy Clin Immunol* 2000;**106**:507-13.
38. Krawiec ME, Westcott JY, Chu HW *et al*. Persistent wheezing in very young children is associated with lower respiratory inflammation. *Am J Respir Crit Care Med* 2001;

- 163:1338-43.
39. Reijonen T, Korppi M, Kuikka L, Remes K. Anti-inflammatory therapy reduces wheezing after bronchiolitis. *Arch Pediatr Adolesc Med* 1996;**150**:512-7.
 40. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. *Am J Respir Crit Care Med* 2003;**167**:379-83.
 41. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. *N Engl J Med* 2006;**354**:1998-2005.
 42. Simpson A, Custovic A. Allergen avoidance in the primary prevention of asthma. *Curr Opin Allergy Clin Immunol* 2004;**4**:45-51.
 43. Korppi M, Kotaniemi-Syrjanen A, Waris M, Vainionpaa R, Reijonen TM. Rhinovirus-associated wheezing in infancy: comparison with respiratory syncytial virus bronchiolitis. *Pediatr Infect Dis J* 2004;**23**:995-9.
 44. Kim HH, Lee MH, Lee JS. Eosinophil cationic protein and chemokines in nasopharyngeal secretions of infants with respiratory syncytial virus (RSV) bronchiolitis and non-RSV bronchiolitis. *J Korean Med Sci* 2007;**22**:37-42.
 45. Saito T, Deskin RW, Casola A *et al*. Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells. *J Infect Dis* 1997;**175**:497-504.
 46. Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. Respiratory syncytial virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. *Am J Respir Crit Care Med* 1999;**159**:1918-24.
 47. Kimpen JL, Garofalo R, Welliver RC, Fujihara K, Ogra PL. An ultrastructural study of the interaction of human eosinophils with respiratory syncytial virus. *Pediatr Allergy Immunol* 1996;**7**:48-53.
 48. Olszewska-Pazdrak B, Pazdrak K, Ogra PL, Garofalo RP. Respiratory syncytial virus-infected pulmonary epithelial cells induce eosinophil degranulation by a CD18-mediated mechanism. *J Immunol* 1998;**160**:4889-95.
 49. Matsumoto K, Shimanouchi Y, Kawakubo K *et al*. Infantile eczema at one month of age is associated with cord blood eosinophilia and subsequent development of atopic dermatitis and wheezing illness until two years of age. *Int Arch Allergy Immunol* 2005;**137**(Suppl1):69-76.
 50. Matsumoto K, Tamari M, Saito H. Involvement of eosinophils in the onset of asthma. *J Allergy Clin Immunol* 2008;**121**:26-7.